Open-label phase 3b clinical study to evaluate the immunogenicity and safety of FSME-IMMUN 0.5 ml with the first and second vaccination being administered according to a rapid immunization schedule in healthy adults aged 16 years or older
Latest Information Update: 25 Jan 2021
At a glance
- Drugs Tick-borne encephalitis vaccine (Primary)
- Indications Encephalitis
- Focus Pharmacodynamics; Registrational
- Sponsors Baxter Healthcare Corporation; Pfizer
- 12 Oct 2012 Trial status is active, no longer recruiting as reported by ClinicalTrials.gov (Extension study: NCT01582698).
- 12 Oct 2012 Trial status is active, no longer recruiting as reported by ClinicalTrials.gov (Extension study: NCT01582698).
- 12 Oct 2012 Trial status is active, no longer recruiting as reported by ClinicalTrials.gov (Extension study: NCT01582698).